A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
195actual
Sites
23
Countries
Bulgaria, Canada, Israel +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-20 | actual | When the study began enrolling |
| Primary completion | 2026-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Thromboembolism
Interventions
- Drug: REGN9933
- Drug: REGN7508
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of confirmed VTE per central reading center (CRC) review
measured Through Day 14
Incidence of treatment-emergent adverse event (TEAEs)
measured Up to Day 100
Severity of TEAEs
measured Up to Day 100
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed